Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX.
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.
JCO Oncol Pract. 2020 Mar;16(3):103-109. doi: 10.1200/JOP.19.00652. Epub 2020 Feb 3.
Mucositis is a common and feared complication of anticancer therapy that can affect up to 90% of certain populations of patients with cancer. Even seemingly uncomplicated mucositis, which is often self-limited, can result in intense patient discomfort and decline in quality of life. Severe mucositis can be complicated by uncontrolled pain, superinfection or systemic infection, bleeding, and dehydration, and severe mucositis can lead to interruptions or de-escalation in anticancer treatment, resulting in worse oncologic outcomes. This article provides an evidence-based summary to guide practicing oncologists in the assessment, prevention, and management of mucositis induced by chemotherapy, radiotherapy, and targeted therapy.
黏膜炎是癌症治疗中一种常见且令人恐惧的并发症,可影响高达 90%的特定癌症患者人群。即使是看似不复杂的、通常具有自限性的黏膜炎,也会导致患者极度不适和生活质量下降。严重的黏膜炎可并发无法控制的疼痛、继发感染或全身感染、出血和脱水,严重的黏膜炎可导致抗癌治疗中断或降级,从而导致肿瘤学结局恶化。本文提供了循证总结,以指导肿瘤临床医生评估、预防和治疗化疗、放疗和靶向治疗引起的黏膜炎。